HENRY S. FRIEDMAN, M.D., F.A.C.P.                  

 click to view this physician's blog

Click here for full CV

Click here to listen to a radio interview with Dr. Friedman

EXPERTISE: Brain Cancers

Deputy Director, at The Preston Robert Tisch Brain Tumor Center Duke University


Fellowship: Pediatric Hematology/Oncology, Duke University Medical Center

Research Fellowship: Pediatric Hematology/Oncology, Upstate Medical Center, Syracuse, NY 


    Residencies: Pediatrics, SUNY Upstate Medical University of Syracuse (New York), Pediatric Hematology/Oncology, Upstate Medical Center (New York)

    Medical School: M.D. SUNY Upstate Medical University College of Medicine (New York)

    School: B.A University of Rochester, Rochester, NY


    • Citation, Upstate Medical Center, 1977


    • F. Wayne Rundles Award for Outstanding Cancer Research, Duke University Comprehensive Cancer Center, 1990
    • Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer, 2010
    • Visionary Award, Tug McGraw Foundation, 2010


    • American Board of Pediatrics
    • Sub - Board of Hematology/Oncology


    • Assistant Professor Pathology, Duke University Medical, Durham, NC
    • Member- Cancer Center, Duke University Medical Center, Durham, NC
    • Senior Investigator, Module 1, Cancer Center Isolation Facility, Duke University Medical Center, Durham, NC
    • Professor of Pediatrics with Tenure, Duke University Medical Center, Durham, NC
    • Associate Chief of Preuss Laboratory for Brain Tumor Research, Duke University Medical Center, Durham, NC
    • Graduate Faculty (Pathology) of the Graduate School, Duke University Medical Center, Durham, NC
    • Chief Division of Pediatric Neuro - Oncology, Duke University Medical Center, Durham, NC
    • Associate Professor of Medicine, Duke University Medical Center, Durham, NC
    • Associate Professor of Surgery, Duke University Medical Center, Durham, NC
    • Co-Director, Clinical Neuro-Oncology Program, Duke University Medical Center, Durham, NC
    • James B. Powell, Jr. Professor of Neuro-Oncology, Duke University Medical Center, Durham, NC
    • Co-Deputy Director, The Preston Roberty Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC
    • Associate Director for Clinical Research, Neuro- Oncology Program, Duke Cancer Institute, Duke University Medical Center, Durham, NC



    • Fellow, American Academy of Pediatrics, 1982- present


    • North Carolina Pediatric Society, 1982-present
    • Pediatric Oncology Group, 1982- present
    • Pediatric Oncology Group: Brain Tumor Core Committee, 1983- present
    • Pediatric Oncology Group: Vice-Chairperson, Brain Tumor Core-Committee, 1988-1991
    • Southern Society for Pediatric Research, 1983-present
    • American Society of Clinical Oncology, 1985- present
    • American Association for Neuropathology, 1985-present
    • American Association for Advancement of Science, 1985-present
    • American Association for Cancer Research, 1986-present
    • Society for Pediatric Research, 1986-present
    • American Cancer Society: Professional Education Committee 1990-1994
    • American Cancer Society (NC Division): Board of Directors 1991-1994
    • Pediatric Oncology Group: Chairperson, Brain Tumor Core Committee, 1991-2000
    • Society for Neuro-Oncology, 1994-present
    • American Society for Clinical Investigation, 1994-Present
    • American Society of Clinical Oncology: Cancer Education Committee, 2000-present
    • Tug McGraw Foundation, Chairperson, Medical Advisory Council, 2006-present




      • Biology and Therapeutic Profile of Central Nervous System Tumors: Dr. Friedman has established the most rigorously studied models of human medulloblastoma, ependymoma and childhood and adult glioma extant.  He in the past had longstanding collaborative relationships with Dr. O. Michael Colvin studying alkylator cytotoxicity and resistance in medulloblastoma; with Dr. Owen Griffith of the Medical College of Milwaukee studying central nervous system metabolism of glutathione, with Dr. Eileen Dolan of the University of Chicago and Dr. Tony Pegg of Penn State University studying modulation of CNS tumor alkyltransferase activity, and with Dr. Paul Modrich and Dr. Francis Ali-Osman studying mismatch repair deficiency and methylator resistance.  Most recently his laboratory work has focused on the evaluation of novel agents in high-grade glioma and medulloblastoma. As a member of the Duke Cancer Institute, Dr. Friedman functions as the senior investigator in charge of Module 1 of the CCIF, as well as conducting his studies identified above in medulloblastomas, ependymomas and childhood gliomas grown in athymic nude mice.
      • Clinical Investigation: Dr. Friedman's major area of clinical investigation is in the therapy of children and
        adults with newly diagnosed and recurrent brain tumors. He is the co-Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke and the Associate Director of Clinical Research, Neuro-Oncology Program, Duke Cancer Institute and designs clinical trials for children and adults with brain tumors seen at Duke (seeing 70-100 new patients per month).